Ipca Laboratories Balance Sheet Health
Financial Health criteria checks 5/6
Ipca Laboratories has a total shareholder equity of ₹88.7B and total debt of ₹12.1B, which brings its debt-to-equity ratio to 13.6%. Its total assets and total liabilities are ₹122.6B and ₹34.0B respectively. Ipca Laboratories's EBIT is ₹14.2B making its interest coverage ratio 34.9. It has cash and short-term investments of ₹12.5B.
Key information
13.59%
Debt to equity ratio
₹12.05b
Debt
| Interest coverage ratio | 34.9x |
| Cash | ₹12.55b |
| Equity | ₹88.66b |
| Total liabilities | ₹33.97b |
| Total assets | ₹122.63b |
Recent financial health updates
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Jan 10
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Recent updates
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Dec 09Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
Oct 19If EPS Growth Is Important To You, Ipca Laboratories (NSE:IPCALAB) Presents An Opportunity
Sep 05The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 15Ipca Laboratories (NSE:IPCALAB) Will Pay A Dividend Of ₹2.00
Jul 08Ipca Laboratories' (NSE:IPCALAB) Dividend Will Be ₹2.00
Jun 24Ipca Laboratories Limited Just Missed Earnings - But Analysts Have Updated Their Models
Jun 01Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
May 22Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 16Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Jan 10Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
Dec 20
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
Nov 17Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Sep 10Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
Jun 07Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
May 24Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Aug 31Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
May 28Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Mar 15These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well
Sep 20Financial Position Analysis
Short Term Liabilities: IPCALAB's short term assets (₹65.2B) exceed its short term liabilities (₹25.4B).
Long Term Liabilities: IPCALAB's short term assets (₹65.2B) exceed its long term liabilities (₹8.6B).
Debt to Equity History and Analysis
Debt Level: IPCALAB has more cash than its total debt.
Reducing Debt: IPCALAB's debt to equity ratio has increased from 7.3% to 13.6% over the past 5 years.
Debt Coverage: IPCALAB's debt is well covered by operating cash flow (113%).
Interest Coverage: IPCALAB's interest payments on its debt are well covered by EBIT (34.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/16 07:50 |
| End of Day Share Price | 2026/01/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ipca Laboratories Limited is covered by 41 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Sanjeev Chiniwar | Anand Rathi Shares and Stock Brokers Limited |